Neurodegenerative diseases
As our global population grows, age-related conditions like neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and ALS, are more widespread. Today, these diseases affect over 65 million people worldwide, causing the people who suffer from them to experience a sharp decline in cognitive and physical functions. Though hundreds of neurodegenerative diseases exist, there are currently few treatments and no cures. Neurodegenerative diseases are incredibly complex, with many factors, including genetics and environmental influences, contributing to their onset and progression. Rick Myers, PhD, Chief Scientific Officer, and Nick Cochran, PhD, Faculty Investigator , are committed to better understanding the genetics of neurodegenerative diseases, working to improve the diagnosis, treatment, and monitoring of these conditions and bringing us closer to more effective solutions. THE MEMORY & MOBILITY PROGRAM POWERS DISCOVERIES The Memory and Mobility (M&M) Program is fueled by philanthropy to support HudsonAlpha’s vital research on neurodegenerative diseases.
Rick Myers, PhD & Nick Cochran, PhD
ALS Through support from the M&M Program and the ALS Association , the Myers lab leads an exciting study in collaboration with Crestwood Medical Center’s ALS Care Clinic . Researchers are studying samples provided by ALS patients in our community to identify and validate a biomarker linked to ALS. This biomarker would help improve ALS diagnostics and inform treatment by monitoring disease progression.
Made with FlippingBook - Online magazine maker